Neuroprotection and imaging studies in Parkinson's disease.


The most challenging issue when testing putative neuroprotective agents for Parkinson's disease (PD) in clinical trials is the assessment of the effect of the treatment on the neurodegenerative process. By measuring changes in symptoms severity, clinical rating scales represent an important tool to rate the progression of the disease. However, the rating of… (More)
DOI: 10.1016/S1353-8020(09)70832-6


1 Figure or Table